WAP
ALNY icon

Wealthcare Advisory Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Wealthcare Advisory Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$385K Sell
1,280
-50
-4% -$15.1K 0.01% 792
2026
Q1 		$440K Buy
1,330
+19
+1% +$6.47K 0.01% 745
2025
Q4 		$521K Buy
+1,311
New +$580K 0.01% 684

Other funds holding ALNY

CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
MIF
Mediolanum International Funds Dublin 1, Ireland $11.7B AUM 47.18% 1-Year Est. Return
SSA
Sierra Summit Advisors Incline Village, Nevada $895M AUM 106% 1-Year Est. Return
FISPB
Fideuram - Intesa Sanpaolo Private Banking Turin $3.33B AUM
OIAM
OFI Invest Asset Management Paris, France $10B AUM 48.47% 1-Year Est. Return

Wealthcare Advisory Partners's ALNY Position: Q2 2026 in Review

Wealthcare Advisory Partners reduced its Alnylam Pharmaceuticals (ALNY) stake by 3.8% in Q2 2026, selling an estimated $15.1K and leaving 1,280 shares worth $385K. The position accounts for 0.01% of the portfolio, ranked #792.

Wealthcare Advisory Partners first reported a position in ALNY in Q4 2025 and has held it in 3 quarters since. The position peaked at $521K in Q4 2025. 149 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Wealthcare Advisory Partners held 1,280 shares of Alnylam Pharmaceuticals worth $385K as of Q2 2026.
  • Wealthcare Advisory Partners sold 50 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $15.1K.
  • Alnylam Pharmaceuticals made up 0.01% of Wealthcare Advisory Partners's portfolio in Q2 2026, its #792 holding.
  • Wealthcare Advisory Partners first reported a position in Alnylam Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Wealthcare Advisory Partners's Alnylam Pharmaceuticals position peaked at $521K in Q4 2025.
  • 149 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Wealthcare Advisory Partners's 13F filing for Q2 2026, filed 9 Jul 2026.